NDNafeesa N. Dhalwani

Nafeesa N. Dhalwani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nafeesa N. Dhalwani has a total of 229 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-world comparative effectiveness of evolocumab versus ezetimibe in adults with atherosclerotic cardiovascular disease: an active-comparator new-user study

    by Nihar Desai, Ran Jin, Kathleen Hurwitz, Nafeesa N. Dhalwani, Nuvan Rathnayaka, Shia T. Kent, Neil A. Accortt, Timothy L. Lash, Paul Muntner, Chris P. Gale, et al.

  • Open Access

    Real‐World Effectiveness of Evolocumab in Reducing Major Adverse Cardiovascular Events: A Cohort Study

    by Ran Jin, Kathleen Hurwitz, Nafeesa Dhalwani, Shia T. Kent, Leah Jackman, Neil Accortt, M. Alan Brookhart, Lisa Head, Edward Chia Cheng Lai, Nihar R. Desai

    Background: Evolocumab reduces major adverse cardiovascular events in randomized trials, but evidence of its effectiveness in real‐world clinical practice remains limited. Methods: US adults with atherosclerotic cardiovascular disease who initiated evolocumab between 2017 and 2023 were identified from the Komodo Healthcare Map. At day 75 after initiation (index date), patients were classified as treated (remained on evolocumab) or nontreated (discontinued evolocumab before day 75). Patients were followed until the earliest of outcome occurrence, evolocumab discontinuation (treated group) or reinitiation (nontreated group), insurance disenrollment, end of database, or death. The primary outcome was a composite of myocardial infarction, stroke, or coronary revascularization; the secondary outcome was a composite of myocardial infarction, stroke, or cardiovascular disease death. Four‐year cumulative incidence, risk ratios (RR), and 95% CIs were estimated, adjusting for confounders and informative censoring using inverse probability of treatment and censoring weights. Negative control outcomes were used to assess residual confounding before initiating comparative outcome analyses. Results: After weighting, baseline characteristics were well balanced between treated (n=87 102) and nontreated (n=24 609) groups. At 4 years, treated patients had a 20% lower risk of the primary outcome (RR, 0.80 [95% CI, 0.73–0.86]) and a 29% lower risk of the secondary outcome (RR, 0.71 [95% CI, 0.64–0.78]) compared with nontreated patients. Conclusions: In a large, diverse, real‐world population with atherosclerotic cardiovascular disease, evolocumab use was associated with significant reductions in major adverse cardiovascular events, supporting the effectiveness of guideline‐recommended PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor therapy in routine clinical practice.

  • Open Access

    Methodological Challenges of Emulating a Target Trial to Assess Effectiveness of Timing of PCSK9 Inhibitor Treatment Initiation Post Myocardial Infarction

    by Thomas Cars, Stefan Gustafsson, Queenie Chan, Nafeesa Dhalwani, Shia T. Kent, Andrew Briggs, Chris P. Gale, Anselm Gitt, J. Wouter Jukema, Philippe Gabriel Steg, et al.

    Background: Studies comparing treatment strategies based on initiation timing—such as starting PCSK9 inhibitor (PCSK9i) therapy sooner versus later after a myocardial infarction (MI)—are prone to immortal time bias. Clone‐censor‐weight methods can address these issues and allow the researcher to emulate a trial in which patients are assigned to protocols dictating when PCSK9i is initiated. This study aimed to evaluate the comparability of patients in a clone‐censor‐weight setup who initiated a PCSK9i within 12 months post‐MI versus non‐initiators. Methods: We included adult patients hospitalized for MI in Sweden (2015–2021) and followed them for 3 years. We considered two treatment strategies: initiating PCSK9i within 12 months versus not initiating PCSK9i during the same period. We applied the clone‐censor‐weight method to address immortal time bias and assessed remaining bias using covariate balance metrics and negative control outcomes. Results: The primary study sample included 38 627 episodes of MI, with 561 (1.5%) initiating PCSK9i treatment within 12 months. These patients were younger, had higher baseline LDL‐C levels, and were more frequently treated with ezetimibe during their post‐MI follow‐up compared to non‐initiators. Although clone‐censor‐weight estimation was free of immortal time bias, it faced challenges in achieving adequate balance of covariates due to the high rates of censoring (relatively small number of people initiating a PCSK9i in the first year) and strong association between covariates and censoring. Truncation of weights provided more stable estimates but at the expense of some covariate imbalances. Conclusions: The clone‐censor‐weight method is a promising approach that allows researchers to answer questions about the effect of treatment policies. But practical guidance is needed to address problems that arise from small, highly imbalanced groups, which is common with most newly introduced treatments.

  • Open Access

    Identifying Myocardial Infarction and Ischemic Stroke Events in China Real-World Data: A Validation Study in Tianjin Regional Healthcare Database

    by Jiamei Liu, Zizhao Zhang, Yin Liu, Liming Zhao, Zhenna Huang, Xuxiao Ye, Jeff L. Lange, Nafeesa Dhalwani, Fan Yang, Kangyin Chen, et al.

    Objectives: Real-world evidence that supports decision-making must meet numerous criteria, including validated identification of clinical outcomes. This study aimed to develop and validate a method for identifying new cases of myocardial infarction (MI) and ischemic stroke (IS) within real-world clinical data in China. Methods: Algorithms to identify MI and IS events were developed using ICD-10-CM codes and Chinese diagnosis keywords within the Tianjin Regional Healthcare Database. Validation followed predefined criteria: MI required cardiac troponin elevation and ischemic symptoms or cardiac troponin elevation and electrocardiogram changes; IS required clinical symptoms and neuroimaging confirmation of cerebral Magnetic Resonance Imaging (MRI) or Computerized Tomography (CT) reports. Positive predictive value (PPV) with 95% confidence intervals (CI) was calculated for each outcome. Results: Among 304 MI and 302 IS cases randomly selected, approximately half were identified using ICD-10-CM codes and half through Chinese diagnosis keywords. Overall PPV for MI was 69% (95% CI: 63–74%), with similar PPVs across identification methods. PPV increased to 88% for inpatient MI and 97% for primary inpatient MI. For IS, overall PPV was 65% (95% CI: 58–71%), with higher PPV for cases identified by ICD-10-CM codes (76%) compared to keyword-only cases (56%). PPV increased to 76% for inpatient IS and 91% for primary inpatient IS. Conclusions: The use of ICD-10-CM codes and Chinese diagnosis keywords in primary inpatient diagnoses provides a validated approach for the identification of clinical outcomes of MI and IS within real-world clinical data in China.

  • Open Access

    Comparing PCSK9 Monoclonal Antibody Treatment Strategies Following Myocardial Infarction Using Negative Control Outcomes: A Target Trial Emulation Study

    by Rosa Sloot, Alexander Breskin, Lisandro D. Colantonio, Andrew G. Allmon, Ying Yu, Swati Sakhuja, Ligong Chen, Paul Muntner, M. Alan Brookhart, Nafeesa Dhalwani

    Background: Initiation of proprotein convertase subtilisin/kexin type 9 monoclonal antibody (PCSK9 mAb) for lipid-lowering following myocardial infarction (MI) is likely affected by patients’ prognostic factors, potentially leading to bias when comparing real-world treatment effects. Methods: Using target-trial emulation, we assessed potential confounding when comparing two treatment strategies post-MI: initiation of PCSK9 mAb within 1 year and no initiation of PCSK9 mAb. We identified MI hospitalizations during July 2015–June 2020 for patients aged ≥18 years in Optum’s de-identified Clinformatics Data Mart (CDM) and MarketScan, and those aged ≥66 in the US Medicare claims database. We estimated a 3-year counterfactual cumulative risk and risk difference (RD) for 10 negative control outcomes using the clone–censor–weight approach to address time-varying confounding and immortal person-time. Results: PCSK9 mAb initiation within 1-year post-MI was low (0.7% in MarketScan and 0.4% in both CDM and Medicare databases). In CDM, there was a lower risk for cancer (RD = −3.6% [95% CI: −4.3%, −2.9%]), decubitus ulcer (RD = −7.7% [95% CI: −11.8%, −3.7%]), fracture (RD = −8.1% [95% CI: −9.6%, −6.6%]), influenza vaccine (RD = −9.3% [95% CI: −17.5%, −1.1%]), and visual test (RD = −0.6% [95% CI: −0.7%, −0.6%]) under the PCSK9 mAb initiation versus no initiation strategy. Similar differences persisted in the MarketScan and Medicare databases. In each database, ezetimibe and low-density lipoprotein testing were unbalanced between treatment strategies. Conclusion: A comparative effectiveness study of these treatments using the current approach would likely bias results due to the low number of PCSK9 mAb initiators.


  • Recurrent Atherosclerotic Cardiovascular Disease Events Potentially Prevented with Guideline-Recommended Cholesterol-Lowering Therapy following Myocardial Infarction

    by Swati Sakhuja, Vera A. Bittner, Todd M. Brown, Michael E. Farkouh, Emily B. Levitan, Monika M. Safford, Mark Woodward, Ligong Chen, Ruoyan Sun, Nafeesa Dhalwani, et al.

    Purpose Many adults with atherosclerotic cardiovascular disease (ASCVD) who are recommended to take a statin, ezetimibe and/or a proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) by the 2018 American Heart Association/American College of Cardiology cholesterol guideline do not receive these medications. We estimated the percentage of recurrent ASCVD events potentially prevented with guideline-recommended cholesterol-lowering therapy following a myocardial infarction (MI) hospitalization. Methods We conducted simulations using data from US adults with government health insurance through Medicare or commercial health insurance in the MarketScan database. We used data from patients with an MI hospitalization in 2018–2019 to estimate the percentage receiving guideline-recommended therapy. We used data from patients with an MI hospitalization in 2013–2016 to estimate the 3-year cumulative incidence of recurrent ASCVD events (i.e., MI, coronary revascularization or ischemic stroke). The low-density lipoprotein cholesterol (LDL-C) reduction with guideline-recommended therapy was derived from trials of statins, ezetimibe and PCSK9i, and the associated ASCVD risk reduction was estimated from a meta-analysis by the Cholesterol-Lowering Treatment Trialists Collaboration. Results Among 279,395 patients with an MI hospitalization in 2018–2019 (mean age 75 years, mean LDL-C 92 mg/dL), 27.3% were receiving guideline-recommended cholesterol-lowering therapy. With current cholesterol-lowering therapy use, 25.3% (95%CI: 25.2%-25.4%) of patients had an ASCVD event over 3 years. If all patients were to receive guideline-recommended therapy, 19.8% (95%CI: 19.5%-19.9%) were estimated to have an ASCVD event over 3 years, representing a 21.6% (95%CI: 20.5%-23.6%) relative risk reduction. Conclusion Implementation of guideline-recommended cholesterol-lowering therapy could prevent a substantial percentage of recurrent ASCVD events.


  • Open Access

    Evolocumab treatment is associated with early and sustained reductions in low-density cholesterol (LDL-C) over 30 months: final results from the pan-European observational HEYMANS registry

    by K K Ray, P Perrone-Filardi, C Ebenbichler, A Vogt, I Bridges, M Sibartie, N N Dhalwani

    Background: Variability in LDL-C control at a population level associates with worse CV outcomes. This could in part be related to variations in patient adherence to self-administration regimens or variability in the response to a given therapy. Potent therapies such as PCSK9 inhibitors (PCSK9i) reduce cardiovascular events but some have questioned whether these therapies, which require dosing every 2 weeks, can offer sustained population level control of LDL-C. Purpose: Using data from the HEYMANS registry, the objective of these analyses was to evaluate, at a population level, various metrics of variability in LDL-C reduction over time with evolocumab treatment. Methods: HEYMANS was a prospective registry including adults initiating evolocumab treatment in clinical practice in 12 European countries between August 2015 to June 2020. Patient data were collected for ≤6 months before evolocumab initiation (baseline) and ≤30 months post initiation. LDL-C measurements were collected per clinical practice. At each 3-month time point in the study, we analysed median (and 95% CI) reductions in LDL-C, and the proportion of patients achieving ≥30% and ≥50% reductions in LDL-C from baseline. Results: Data from 1951 patients were included in this final analysis (62% male, mean age 60 years, median baseline LDL-C 3.98 [Q1–Q3 3.17–5.07]) mmol/L). Most patients (85%) were receiving evolocumab for secondary prevention, with 40% not on oral LLT of whom the majority reported a history of statin intolerance. There was a median of 4 (Q1, Q3: 2, 6) LDL-C measurements per patient during follow-up. Within 3 months of initiating evolocumab treatment, LDL-C levels had reduced by a median of 58% and this reduction was maintained over 30 months (Figure 1). Among patients with an LDL-C value, ∼85% achieved a ≥30% reduction at each follow-up throughout the study, and ∼63% achieved a ≥50% reduction at each visit (Figure 2). Conclusions: In European clinical practice, evolocumab treatment was associated with early and sustained reductions in LDL-C of over 30 months, with limited variability in LDL-C reductions at a population level. Within 3 months of treatment, evolocumab was associated with ∼58% reduction in LDL-C levels that was maintained throughout the study. These data should reassure the clinical community that meaningful, consistent additional reductions in LDL-C can be achieved with use of evolocumab. As greater use of combination therapies is required to achieve lower LDL-C goals, expanding the use of PCSK9i could provide improvements in population level control of LDL-C in European clinical practice. Funding Acknowledgement: Type of funding sources: Private company. Main funding source(s): Amgen (Europe) GmbH

  • Open Access

    High long-term persistence to evolocumab treatment regimens in European clinical practice: analysis of the HEYMANS registry

    by K K Ray, P Perrone-Filardi, C Ebenbichler, A Vogt, I Bridges, M Sibartie, N N Dhalwani

    Background: Lipid-lowering treatments (LLTs) require both adherence and persistence to the treatment regimen long-term to maximise treatment benefits. Small molecules require self-medication daily but therapies such as evolocumab are labelled for self-medication every 2 weeks or monthly. Limited data exist concerning the long-term persistence to evolocumab in routine clinical practice. Purpose: Using data from the HEYMANS registry, the objective of this analysis was to evaluate persistence and discontinuation of evolocumab in Europe. Methods: HEYMANS was a prospective registry including adults initiating evolocumab treatment in routine clinical practice in 12 European countries between August 2015 and June 2020. Originally designed to have up to 12 months of follow-up, the protocol was amended (February 2018) to extend follow-up for up to 30 months. Patients yet to complete 12 months follow-up at this date, were followed up for up to 30 months. Therefore, we analysed evolocumab discontinuation separately for the two time periods: 0–12 months (all), 12–30 months (subset). Results: Of the 1951 total patients, 30 patients discontinued participation in the study before 12 months (evolocumab use still ongoing at study discontinuation). Therefore, evolocumab use status was determined for 1921 patients at 12 months. Of these, 1781 (92.7%), remained on evolocumab at 12 months of follow-up (Figure). At 12 months, LDL-C levels were reduced from baseline by a median of 58% (Q1, Q3: 41%, 69%). In total, 1136 patients were eligible for extended follow up after protocol amendment. Of these, 137 patients discontinued study participation before 30 months of follow-up (with evolocumab ongoing). Therefore, evolocumab use status was determined in 999 patients, of whom, 92.2% (921) remained on evolocumab treatment at 30 months of follow-up (Figure). The reductions in LDL-C levels seen at 12 months were sustained throughout the study, with patients continuing to achieve median LDL-C reductions of 58% (Q1, Q3: 42%, 70%) from baseline at 30 months of follow-up. Conclusions: In this real-world study, representative of European practice, of patients who entered the extension phase, the proportion of patients who remained on evolocumab up to 30 months exceeded 90%, and treatment was associated with sustained LDL-C reductions. These data suggest that the self-administration regimen of evolocumab is both feasible and acceptable in general populations, providing long-term sustained, reductions in LDL-C with likely associated health benefits. Funding Acknowledgement: Type of funding sources: Private company. Main funding source(s): Amgen (Europe) GmbH

  • Open Access

    Estimating life expectancy and years of life lost in epidemiological studies: a review of methods using an example from multimorbidity

    by Yogini V Chudasama, Kamlesh Khunti, Clare L Gillies, Nafeesa N Dhalwani, Melanie J Davies, Thomas Yates, Francesco Zaccardi

    Background and objective There has been an increasing interest in using life expectancy metrics, such as years of life lost (YLL), to explore epidemiological associations. YLL is easier to understand for both healthcare professionals and the lay people and has become a common measure for evaluating public health priorities. As the literature presents a range of approaches to estimate it, this review aims to: (1) summarise the key methods; (2) show how to implement them using current software; (3) apply them in a real-world example. Methods We investigated simpler nonparametric as well as parametric, model-based methods to estimate of YLL, including: (1) Years of potential life lost (YPLL); (2) Global Burden of Disease (GBD) approach; (3) Chiang’s life tables; (4) Epi-demographic approach; and (5) Flexible Royston-Parmar parametric survival model. We used data from the UK Biobank with baseline measures collected in 2006-2010 and linkage to mortality records. We selected 36 chronic conditions: participants with two or more conditions were categorised as having multimorbidity. Results For the YPLL and GBD method, the analytical procedures allow only to quantify the average YLL within each group (with and without multimorbidity) and, from them, their difference. Conversely, for the Chiang’s life tables, the epi-demographic approach, and the Royston-Parmar survival model, both the remaining life expectancy within each group and the YLL could be estimated. In 499,992 UK Biobank participants (white ethnicity, 94%; women, 55%) with a median (IQR) age of 58 (50-63) years, 98,605 (20%) had multimorbidity and 11,871 deaths occurred during the follow-up. The YLLs comparing subjects with vs without multimorbidity varied significantly according to the technique and the modelling approach used: from a longer life expectancy in subjects with multimorbidity using the YPLL and the GBD method to a shorter one using the other three methods (i.e., at 65 years, the YLL were 1.8, 1.3, and 4.6 years using Chiang’s, epi-demographic, and Royston-Parmar approach, respectively). Conclusions When comparing the burden of a disease on life expectancy across studies caution is needed as methods may estimate different quantities. While deciding among different methods to estimate YLL, researchers should consider such differences in relation to the purpose of the research and the type of available data. SUMMARY BOX The concept of years of life lost (YLL) is easier to understand compared to traditional estimates from survival analysis, such as hazard ratios, but very few studies report it. A range of different methods of estimating YLL are reviewed: from basic methods – such as life tables – to most recent and advanced methods using statistical modelling. Using the example of multimorbidity, the estimated numbers of YLL differs between methods, as each method focused on estimating different quantities. This review will help promote a better understanding and use of life expectancy and YLL metrics in a wide range of studies in health care research.

  • Open Access

    Associations of Hemoglobin Levels With Health-Related Quality of Life, Physical Activity, and Clinical Outcomes in Persons With Stage 3-5 Nondialysis CKD

    by Junichi Hoshino, Daniel Muenz, Jarcy Zee, Nidhi Sukul, Elodie Speyer, Murilo Guedes, Antonio A. Lopes, Koichi Asahi, Heleen van Haalen, Glen James, et al.